This is, for example, what could be envisaged for patient MA01, whose tumor organoid was particularly sensitive to the mTOR inhibitor, everolimus, as well as to crizotinib, foretinib, and dasatinib, drugs that do not target mTOR. Here, MTOR is linked to neoplasm.